Gln/Gln Arg/Arg Gln/Gln Arg/Gly Gln/Gln Gly/Gly Gln/Glu Arg/Arg Gln/Glu Arg/Gly Gln/Glu Gly/Gly Glu/Glu Arg/Gly Glu/Glu Gly/Gly Participants 11 15 7 3 32 18 5 12 Male 9(81.82%) 14(93.33%) 7(100%) 3(100%) 27(84.38%) 13(72.22%) 5(100%) 10(83.33%) AsthmaStage 1 3(27.27%) 2(13.13%) 0 0 5(15.63%) 1(5.56%) 0 2(16.67%) 2 2(18.18%) 2(13.13%) 2(28.57%) 0 6(18.75%) 8(44.44%) 3(60%) 2(16.67%) 3 5(45.45%) 8(53.33%) 4(57.14%) 1(33.33%) 16(50%) 7(38.39%) 1(20%) 5(41.67%) 4 1(9.09%) 3(20%) 1(14.29%) 2(66.67%) 5(15.63%) 2(11.11%) 1(20%) 3(25%) COPDStage                 1 4(36.36%) 4(26.67%) 0 0 9(28.13%) 6(33.33%) 2(40%) 3(25%) 2 3(27.27%) 6(40%) 4(57.14%) 0 14(43.75%) 6(33.33%) 1(20%) 5(41.67%) 3 3(27.27%) 4(26.67%) 2(28.57%) 2(66.67%) 6(18.75%) 5(27.78%) 1(20%) 2(16.67%) 4 1(9.09%) 1(6.67%) 1(14.29%) 1(33.33%) 3(9.38%) 1(5.56%) 1(20%) 2(16.67%) Exacerbation                 0 5(45.45%) 8(53.33%) 0 0 15(46.88%) 3(16.67%) 2(40%) 5(41.67%) 1 3(27.27%) 3(20%) 5(71.43%) 2(66.67%) 11(34.38%) 13(72.22%) 1(20%) 3(25%) 2 1(9.09%) 2(13.33%) 2(28.57%) 0 4(12.50%) 1(5.56%) 1(20%) 1(8.33%) 3 0 1(6.67%) 0 0 0 0 0 2(16.67%) 4 1(9.09%) 0 0 1(33.33%) 1(3.13%) 1(5.56%) 0 0 5 0 0 0 0 1(3.13%) 0 0 0 6 1(9.09%) 0 0 0 0 0 0 0 8 0 0 0 0 0 0 0 1(8.33%) 12 0 1(6.67%) 0 0 0 0 1(20%) 0 OralSteroid                 0 5(45.45%) 8(53.33%) 1(14.29%) 0 16(50%) 4(22.22%) 2(40%) 5(41.67%) 1 3(27.27%) 3(20%) 4(57.14%) 2(66.67%) 12(37.5%) 11(61.11%) 1(20%) 3(25%) 2 1(9.09%) 2(13.13%) 1(14.29%) 0 2(6.25%) 2(11.11%) 1(20%) 1(8.33%) 3 2(18.18%) 0 0 0 0 0 0 2(16.67%) 4 0 0 1(14.29%) 0 1(3.13%) 1(5.56%) 0 0 5 0 1(6.67%) 0 1(33.33%) 1(3.13%) 0 0 0 8 0 0 0 0 0 0 0 1(8.33%) 13 0 0 0 0 0 0 1(20%) 0 14 0 1(6.67%) 0 0 0 0 0 0

Table 4: Statistical summary of the participants, Asthma stage, COPD stage, Exacerbation and Oral Steroid use by genotype (Arg16Gly and Gln27Glu combination).

Goto home»